Richard K Zimmerman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/450574/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Seasonal Influenza in Adults and Children—Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management: Clinical Practice Guidelines of the Infectious Diseases Society of America. Clinical Infectious Diseases, 2009, 48, 1003-1032.	2.9	604
2	Influenza Vaccine Effectiveness in the 2011–2012 Season: Protection Against Each Circulating Virus and the Effect of Prior Vaccination on Estimates. Clinical Infectious Diseases, 2014, 58, 319-327.	2.9	303
3	Influenza Vaccine Effectiveness in the United States During 2012-2013: Variable Protection by Age and Virus Type. Journal of Infectious Diseases, 2015, 211, 1529-1540.	1.9	245
4	Influenza Vaccine Effectiveness in the United States during the 2015–2016 Season. New England Journal of Medicine, 2017, 377, 534-543.	13.9	240
5	2014–2015 Influenza Vaccine Effectiveness in the United States by Vaccine Type. Clinical Infectious Diseases, 2016, 63, 1564-1573.	2.9	229
6	Sensitivity and specificity of patient self-report of influenza and pneumococcal polysaccharide vaccinations among elderly outpatients in diverse patient care strata. Vaccine, 2003, 21, 1486-1491.	1.7	223
7	Effects of Influenza Vaccination in the United States During the 2017–2018 Influenza Season. Clinical Infectious Diseases, 2019, 69, 1845-1853.	2.9	218
8	What affects influenza vaccination rates among older patients? An analysis from inner-city, suburban, rural, and veterans affairs practices. American Journal of Medicine, 2003, 114, 31-38.	0.6	194
9	Vaccine Criticism on the World Wide Web. Journal of Medical Internet Research, 2005, 7, e17.	2.1	193
10	Influenza Vaccine Effectiveness Against 2009 Pandemic Influenza A(H1N1) Virus Differed by Vaccine Type During 2013–2014 in the United States. Journal of Infectious Diseases, 2016, 213, 1546-1556.	1.9	159
11	Spread of Antigenically Drifted Influenza A(H3N2) Viruses and Vaccine Effectiveness in the United States During the 2018–2019 Season. Journal of Infectious Diseases, 2020, 221, 8-15.	1.9	150
12	Immunization Programs for Infants, Children, Adolescents, and Adults: Clinical Practice Guidelines by the Infectious Diseases Society of America. Clinical Infectious Diseases, 2009, 49, 817-840.	2.9	146
13	Outpatient Antibiotic Prescribing for Acute Respiratory Infections During Influenza Seasons. JAMA Network Open, 2018, 1, e180243.	2.8	146
14	Interim Estimates of 2017–18 Seasonal Influenza Vaccine Effectiveness — United States, February 2018. Morbidity and Mortality Weekly Report, 2018, 67, 180-185.	9.0	146
15	Simulating School Closure Strategies to Mitigate an Influenza Epidemic. Journal of Public Health Management and Practice, 2010, 16, 252-261.	0.7	145
16	Early estimates of seasonal influenza vaccine effectiveness - United States, January 2015. Morbidity and Mortality Weekly Report, 2015, 64, 10-5.	9.0	144
17	Cost-effectiveness of Adult Vaccination Strategies Using Pneumococcal Conjugate Vaccine Compared With Pneumococcal Polysaccharide Vaccine. JAMA - Journal of the American Medical Association, 2012, 307, 804-12.	3.8	115
18	Improving Influenza Vaccination Rates in the Workplace. American Journal of Preventive Medicine, 2010, 38, 237-246.	1.6	110

#	Article	IF	CITATIONS
19	A computer simulation of vaccine prioritization, allocation, and rationing during the 2009 H1N1 influenza pandemic. Vaccine, 2010, 28, 4875-4879.	1.7	109
20	Enhanced Genetic Characterization of Influenza A(H3N2) Viruses and Vaccine Effectiveness by Genetic Group, 2014–2015. Journal of Infectious Diseases, 2016, 214, 1010-1019.	1.9	101
21	Barriers to Pneumococcal and Influenza Vaccination in Older Community-Dwelling Adults (2000–2001). Journal of the American Geriatrics Society, 2004, 52, 25-30.	1.3	90
22	Interim Estimates of 2016–17 Seasonal Influenza Vaccine Effectiveness — United States, February 2017. Morbidity and Mortality Weekly Report, 2017, 66, 167-171.	9.0	90
23	Influenza Vaccine Effectiveness in the United States During the 2016–2017 Season. Clinical Infectious Diseases, 2019, 68, 1798-1806.	2.9	90
24	Ethical analysis of HPV vaccine policy options. Vaccine, 2006, 24, 4812-4820.	1.7	84
25	A Computer Simulation of Employee Vaccination to Mitigate an Influenza Epidemic. American Journal of Preventive Medicine, 2010, 38, 247-257.	1.6	84
26	Seroprevalence Following the Second Wave of Pandemic 2009 H1N1 Influenza in Pittsburgh, PA, USA. PLoS ONE, 2010, 5, e11601.	1.1	82
27	Seasonal Effectiveness of Live Attenuated and Inactivated Influenza Vaccine. Pediatrics, 2016, 137, e20153279.	1.0	80
28	Barriers to and facilitators of child influenza vaccine – Perspectives from parents, teens, marketing and healthcare professionals. Vaccine, 2012, 30, 2448-2452.	1.7	74
29	Knowledge and Beliefs About Influenza, Pneumococcal Disease, and Immunizations Among Older People. Journal of the American Geriatrics Society, 2002, 50, 1711-1716.	1.3	72
30	Barriers and facilitators of pneumococcal vaccination among the elderly. Vaccine, 2003, 21, 1510-1517.	1.7	68
31	Tailored Interventions to Increase Influenza Vaccination in Neighborhood Health Centers Serving the Disadvantaged. American Journal of Public Health, 2003, 93, 1699-1705.	1.5	68
32	Parental Perspectives on Influenza Immunization of Children Aged 6 to 23 Months. American Journal of Preventive Medicine, 2005, 29, 210-214.	1.6	67
33	Physician and practice factors related to influenza vaccination among the elderly. American Journal of Preventive Medicine, 2004, 26, 1-10.	1.6	65
34	Impact of age and pre-existing influenza immune responses in humans receiving split inactivated influenza vaccine on the induction of the breadth of antibodies to influenza A strains. PLoS ONE, 2017, 12, e0185666.	1.1	60
35	Missed opportunities for adult immunization in diverse primary care office settings. Vaccine, 2004, 22, 3457-3463.	1.7	59
36	Alternative strategies for adult pneumococcal polysaccharide vaccination: A cost-effectiveness analysis. Vaccine, 2008, 26, 1420-1431.	1.7	59

#	Article	IF	CITATIONS
37	Prevention of Influenza Hospitalization Among Adults in the United States, 2015–2016: Results From the US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN). Journal of Infectious Diseases, 2019, 220, 1265-1275.	1.9	59
38	Seroprevalence Following the Second Wave of Pandemic 2009 H1N1 Influenza. PLOS Currents, 2010, 2, RRN1148.	1.4	59
39	Classification and Regression Tree (CART) analysis to predict influenza in primary care patients. BMC Infectious Diseases, 2016, 16, 503.	1.3	57
40	Use of Influenza Antiviral Agents by Ambulatory Care Clinicians During the 2012-2013 Influenza Season. Clinical Infectious Diseases, 2014, 59, 774-782.	2.9	53
41	Interim estimates of 2013-14 seasonal influenza vaccine effectiveness - United States, February 2014. Morbidity and Mortality Weekly Report, 2014, 63, 137-42.	9.0	53
42	Influenza vaccine effectiveness in older adults compared with younger adults over five seasons. Vaccine, 2018, 36, 1272-1278.	1.7	52
43	Beliefs and Attitudes about Influenza Immunization among Parents of Children with Chronic Medical Conditions over a Two-Year Period. Journal of Urban Health, 2006, 83, 874-883.	1.8	49
44	Importance of vaccination habit and vaccine choice on influenza vaccination among healthy working adults. Vaccine, 2010, 28, 7706-7712.	1.7	43
45	The Benefits To All Of Ensuring Equal And Timely Access To Influenza Vaccines In Poor Communities. Health Affairs, 2011, 30, 1141-1150.	2.5	43
46	Influence of Birth Cohort on Effectiveness of 2015–2016 Influenza Vaccine Against Medically Attended Illness Due to 2009 Pandemic Influenza A(H1N1) Virus in the United States. Journal of Infectious Diseases, 2018, 218, 189-196.	1.9	43
47	To Test or to Treat? An Analysis of Influenza Testing and Antiviral Treatment Strategies Using Economic Computer Modeling. PLoS ONE, 2010, 5, e11284.	1.1	42
48	Influenza Vaccine Effectiveness in Inpatient and Outpatient Settings in the United States, 2015–2018. Clinical Infectious Diseases, 2021, 73, 386-392.	2.9	41
49	Modeling of Cost Effectiveness of Pneumococcal Conjugate Vaccination Strategies in U.S. Older Adults. American Journal of Preventive Medicine, 2013, 44, 373-381.	1.6	39
50	Prevalence of high-risk indications for influenza vaccine varies by age, race, and income. Vaccine, 2010, 28, 6470-6477.	1.7	38
51	Impact of hospital policies on health care workers' influenza vaccination rates. American Journal of Infection Control, 2013, 41, 697-701.	1.1	38
52	Influenza and other respiratory virus infections in outpatients with medically attended acute respiratory infection during the 2011â€12 influenza season. Influenza and Other Respiratory Viruses, 2014, 8, 397-405.	1.5	38
53	Vaccination Deep Into a Pandemic Wave. American Journal of Preventive Medicine, 2010, 39, e21-e29.	1.6	37
54	Predictors of colorectal cancer screening in diverse primary care practices. BMC Health Services Research, 2006, 6, 116.	0.9	36

#	Article	IF	CITATIONS
55	Randomized, Controlled Trial of High-Dose Influenza Vaccine Among Frail Residents of Long-Term Care Facilities. Journal of Infectious Diseases, 2015, 211, 1915-1924.	1.9	36
56	Cost-Effectiveness of Procalcitonin-Guided Antibiotic Therapy for Outpatient Management of Acute Respiratory Tract Infections in Adults. Journal of General Internal Medicine, 2014, 29, 579-586.	1.3	35
57	Factorial Design for Improving Influenza Vaccination Among Employees of a Large Health System. Infection Control and Hospital Epidemiology, 2009, 30, 691-697.	1.0	34
58	Economics of employer-sponsored workplace vaccination to prevent pandemic and seasonal influenza. Vaccine, 2010, 28, 5952-5959.	1.7	34
59	Influenza Vaccine Effectiveness for Fully and Partially Vaccinated Children 6 Months to 8 Years Old During 2011–2012 and 2012–2013. Pediatric Infectious Disease Journal, 2016, 35, 299-308.	1.1	34
60	Costâ€Effectiveness and Public Health Effect of Influenza Vaccine Strategies for U.S. Elderly Adults. Journal of the American Geriatrics Society, 2016, 64, 2126-2131.	1.3	34
61	Parental perspectives on influenza vaccination of children with chronic medical conditions. Journal of the National Medical Association, 2006, 98, 148-53.	0.6	34
62	Economic Evaluation of Standing Order Programs for Pneumococcal Vaccination of Hospitalized Elderly Patients. Infection Control and Hospital Epidemiology, 2008, 29, 385-394.	1.0	33
63	Use of Standing Orders for Adult Influenza Vaccination. American Journal of Preventive Medicine, 2011, 40, 144-148.	1.6	33
64	Cost-effectiveness of pneumococcal conjugate vaccination in immunocompromised adults. Vaccine, 2013, 31, 3950-3956.	1.7	33
65	The hidden societal cost of antibiotic resistance per antibiotic prescribed in the United States: an exploratory analysis. BMC Infectious Diseases, 2016, 16, 655.	1.3	33
66	Racial differences in beliefs about genetic screening among patients at inner-city neighborhood health centers. Journal of the National Medical Association, 2006, 98, 370-7.	0.6	33
67	Impact of age and pre-existing immunity on the induction of human antibody responses against influenza B viruses. Human Vaccines and Immunotherapeutics, 2019, 15, 2030-2043.	1.4	32
68	Using Facebookâ"¢ to Recruit College-Age Men for a Human Papillomavirus Vaccine Trial. American Journal of Men's Health, 2016, 10, 110-119.	0.7	31
69	Paid Leave and Access to Telework as Work Attendance Determinants during Acute Respiratory Illness, United States, 2017–2018. Emerging Infectious Diseases, 2020, 26, .	2.0	31
70	Designing and implementing a hospital-based vaccine standing orders program. American Journal of Health-System Pharmacy, 2007, 64, 1096-1102.	0.5	30
71	Randomized Trial of an Alternate Human Papillomavirus Vaccine Administration Schedule in College-Aged Women. Journal of Women's Health, 2010, 19, 1441-1447.	1.5	30
72	Cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds. Vaccine, 2010, 28, 7620-7625.	1.7	30

#	Article	IF	CITATIONS
73	Illness Severity and Work Productivity Loss Among Working Adults With Medically Attended Acute Respiratory Illnesses: US Influenza Vaccine Effectiveness Network 2012–2013. Clinical Infectious Diseases, 2016, 62, civ952.	2.9	30
74	Relative and Absolute Effectiveness of High-Dose and Standard-Dose Influenza Vaccine Against Influenza-Related Hospitalization Among Older Adults—United States, 2015–2017. Clinical Infectious Diseases, 2021, 72, 995-1003.	2.9	29
75	Cluster randomized trial of a toolkit and early vaccine delivery to improve childhood influenza vaccination rates in primary care. Vaccine, 2014, 32, 3656-3663.	1.7	28
76	Determinants of adult vaccination at inner-city health centers: A descriptive study. BMC Family Practice, 2006, 7, 2.	2.9	27
77	Improving Influenza Vaccination Rates of High-Risk Inner-City Children Over 2 Intervention Years. Annals of Family Medicine, 2006, 4, 534-540.	0.9	27
78	Using the 4 Pillars Practice Transformation Program to Increase Pneumococcal Immunizations for Older Adults: A Clusterâ€Randomized Trial. Journal of the American Geriatrics Society, 2017, 65, 114-122.	1.3	27
79	The vaccines for children program. American Journal of Preventive Medicine, 2001, 21, 243-249.	1.6	26
80	From the patient perspective: The economic value of seasonal and H1N1 influenza vaccination. Vaccine, 2011, 29, 2149-2158.	1.7	26
81	What Predicts Influenza Vaccination Status in Older Americans over Several Years?. Journal of the American Geriatrics Society, 2005, 53, 1354-1359.	1.3	25
82	Barriers and Facilitators of Colon Cancer Screening Among Patients At Faith-Based Neighborhood Health Centers. Journal of Community Health, 2005, 30, 55-74.	1.9	25
83	Overcoming Barriers to Establishing an Inpatient Vaccination Program for Pneumococcus Using Standing Orders. Infection Control and Hospital Epidemiology, 2005, 26, 874-881.	1.0	25
84	Cost-Effectiveness of Procalcitonin-Guided Antibiotic Use in Community Acquired Pneumonia. Journal of General Internal Medicine, 2013, 28, 1157-1164.	1.3	25
85	Using the 4 pillarsâ,,¢ practice transformation program to increase adult influenza vaccination and reduce missed opportunities in a randomized cluster trial. BMC Infectious Diseases, 2016, 16, 623.	1.3	25
86	Burden of medically attended influenza infection and cases averted by vaccination – United States, 2013/14 through 2015/16 influenza seasons. Vaccine, 2018, 36, 467-472.	1.7	25
87	Proposed clinical indicators for efficient screening and testing for COVID-19 infection using Classification and Regression Trees (CART) analysis. Human Vaccines and Immunotherapeutics, 2021, 17, 1109-1112.	1.4	25
88	Increasing Pneumococcal Vaccination Rates Among Hospitalized Patients. Infection Control and Hospital Epidemiology, 2003, 24, 526-531.	1.0	24
89	Improving adolescent HPV vaccination in a randomized controlled cluster trial using the 4 Pillarsâ,,¢ practice Transformation Program. Vaccine, 2017, 35, 109-117.	1.7	24
90	Risk Factors for Clostridium difficile Cytotoxin-Positive Diarrhea after Control for Horizontal Transmission. Infection Control and Hospital Epidemiology, 1991, 12, 96-100.	1.0	24

#	Article	IF	CITATIONS
91	Changes in parents' perceptions of infant influenza vaccination over two years. Journal of the National Medical Association, 2007, 99, 636-41.	0.6	24
92	Predictors of Lower Endoscopy Use Among Patients at Three Inner-City Neighborhood Health Centers. Journal of Urban Health, 2006, 83, 221-230.	1.8	23
93	Influenza Antiviral Prescribing for Outpatients With an Acute Respiratory Illness and at High Risk for Influenza-Associated Complications During 5 Influenza Seasons—United States, 2011–2016. Clinical Infectious Diseases, 2018, 66, 1035-1041.	2.9	23
94	The effect of frailty on HAI response to influenza vaccine among community-dwelling adults ≥ 50Âyears of age. Human Vaccines and Immunotherapeutics, 2018, 14, 361-367.	1.4	23
95	Effect of the Vaccines for Children Program on Physician Referral of Children to Public Vaccine Clinics: A Pre-Post Comparison. Pediatrics, 2001, 108, 297-304.	1.0	22
96	The potential economic value of a Staphylococcus aureus vaccine among hemodialysis patients. Vaccine, 2012, 30, 3675-3682.	1.7	22
97	Standing orders for influenza and pneumococcal polysaccharide vaccination: Correlates identified in a national survey of U.S. Primary care physicians. BMC Family Practice, 2012, 13, 22.	2.9	22
98	Viral infections in outpatients with medically attended acute respiratory illness during the 2012–2013 influenza season. BMC Infectious Diseases, 2015, 15, 87.	1.3	22
99	Effectiveness of Trivalent and Quadrivalent Inactivated Vaccines Against Influenza B in the United States, 2011–2012 to 2016–2017. Clinical Infectious Diseases, 2021, 72, 1147-1157.	2.9	22
100	Self-reported influenza vaccination rates among health care workers in a large health system. American Journal of Infection Control, 2008, 36, 574-581.	1.1	21
101	Use of Influenza Antiviral Medications Among Outpatients at High Risk for Influenza-Associated Complications During the 2013–2014 Influenza Season. Clinical Infectious Diseases, 2015, 60, 1677-1680.	2.9	21
102	Homeschooling parents' practices and beliefs about childhood immunizations. Vaccine, 2012, 30, 1149-1153.	1.7	20
103	Helping patients with ethical concerns about COVID-19 vaccines in light of fetal cell lines used in some COVID-19 vaccines. Vaccine, 2021, 39, 4242-4244.	1.7	20
104	Neutralizing Antibody Responses to Antigenically Drifted Influenza A(H3N2) Viruses among Children and Adolescents following 2014-2015 Inactivated and Live Attenuated Influenza Vaccination. Vaccine Journal, 2016, 23, 831-839.	3.2	19
105	Understanding Physician Agreement with Varicella Immunization Guidelines. Preventive Medicine, 2002, 35, 135-142.	1.6	18
106	Understanding Adult Vaccination in Urban, Lower-Socioeconomic Settings: Influence of Physician and Prevention Systems. Annals of Family Medicine, 2009, 7, 534-541.	0.9	18
107	Estimating the cost-effectiveness of a national program to eliminate disparities in influenza vaccination rates among elderly minority groups. Vaccine, 2011, 29, 3525-3530.	1.7	18
108	Evaluation of a toolkit to introduce standing orders for influenza and pneumococcal vaccination in adults: A multimodal pilot project. Vaccine, 2012, 30, 5978-5982.	1.7	18

#	Article	IF	CITATIONS
109	Shortage of influenza vaccine in 2000–2001. American Journal of Preventive Medicine, 2003, 24, 349-353.	1.6	17
110	Influence of pre-existing hemagglutination inhibition titers against historical influenza strains on antibody response to inactivated trivalent influenza vaccine in adults 50–80 years of age. Human Vaccines and Immunotherapeutics, 2014, 10, 1195-1203.	1.4	17
111	Success of the 4 Pillars Toolkit for Influenza and Pneumococcal Vaccination in Adults. Journal for Healthcare Quality: Official Publication of the National Association for Healthcare Quality, 2014, 36, 5-15.	0.3	17
112	Randomized controlled trial of two dosing schedules for human papillomavirus vaccination among college age males. Vaccine, 2014, 32, 693-699.	1.7	17
113	Quantifying the Economic Value and Quality of Life Impact of Earlier Influenza Vaccination. Medical Care, 2015, 53, 218-229.	1.1	17
114	Do vitamin D levels affect antibody titers produced in response to HPV vaccine?. Human Vaccines and Immunotherapeutics, 2015, 11, 2345-2349.	1.4	17
115	Estimating the Impact of Low Influenza Activity in 2020 on Population Immunity and Future Influenza Seasons in the United States. Open Forum Infectious Diseases, 2022, 9, ofab607.	0.4	17
116	Raising Adult Vaccination Rates over 4 Years Among Racially Diverse Patients at Inner ity Health Centers. Journal of the American Geriatrics Society, 2008, 56, 1177-1182.	1.3	16
117	Influenza vaccine effectiveness among patients with high-risk medical conditions in the United States, 2012–2016. Vaccine, 2018, 36, 8047-8053.	1.7	16
118	Predictors of pneumococcal polysaccharide vaccination among patients at three inner-city neighborhood health centers. American Journal of Geriatric Pharmacotherapy, 2005, 3, 149-159.	3.0	15
119	Higher Pneumococcal Disease Vaccination Rates Needed to Protect More At-Risk US Adults. Postgraduate Medicine, 2009, 121, 101-105.	0.9	15
120	Increasing Childhood Influenza Vaccination. American Journal of Preventive Medicine, 2014, 47, 435-443.	1.6	15
121	Low Influenza Vaccine Effectiveness Against A(H3N2)-Associated Hospitalizations in 2016–2017 and 2017–2018 of the Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN). Journal of Infectious Diseases, 2021, 223, 2062-2071.	1.9	15
122	Effects of Prior Season Vaccination on Current Season Vaccine Effectiveness in the United States Flu Vaccine Effectiveness Network, 2012–2013 Through 2017–2018. Clinical Infectious Diseases, 2021, 73, 497-505.	2.9	15
123	Designing a hospital-based pneumococcal vaccination program. American Journal of Health-System Pharmacy, 2003, 60, 1471-1476.	0.5	14
124	Ethical analyses of vaccines grown in human cell strains derived from abortion: arguments and Internet search. Vaccine, 2004, 22, 4238-4244.	1.7	14
125	Rationing of influenza vaccine during a pandemic: Ethical analyses. Vaccine, 2007, 25, 2019-2026.	1.7	14
126	Establish the Habit: Influenza Vaccination for Health Care Personnel. Journal for Healthcare Quality: Official Publication of the National Association for Healthcare Quality, 2010, 32, 35-42.	0.3	14

#	Article	IF	CITATIONS
127	The potential economic value of a â€~universal' (multiâ€year) influenza vaccine. Influenza and Other Respiratory Viruses, 2012, 6, 167-175.	1.5	14
128	Incidence of medically attended influenza infection and cases averted by vaccination, 2011/2012 and 2012/2013 influenza seasons. Vaccine, 2015, 33, 5181-5187.	1.7	14
129	Does cost-effectiveness of influenza vaccine choice vary across the U.S.? An agent-based modeling study. Vaccine, 2017, 35, 3974-3981.	1.7	14
130	Cost-effectiveness of increasing vaccination in high-risk adults aged 18–64ÂYears: a model-based decision analysis. BMC Infectious Diseases, 2018, 18, 52.	1.3	14
131	Relative effectiveness of high dose versus standard dose influenza vaccines in older adult outpatients over four seasons, 2015–16 to 2018–19. Vaccine, 2020, 38, 6562-6569.	1.7	14
132	Differential gene expression in peripheral blood mononuclear cells from children immunized with inactivated influenza vaccine. Human Vaccines and Immunotherapeutics, 2020, 16, 1782-1790.	1.4	14
133	The impact of physical frailty on the response to inactivated influenza vaccine in older adults. Aging, 2020, 12, 24633-24650.	1.4	14
134	Examining Structural and Clinical Factors Associated with Implementation of Standing Orders for Adult Immunization. Journal for Healthcare Quality: Official Publication of the National Association for Healthcare Quality, 2012, 34, 34-42.	0.3	13
135	Does Choice of Influenza Vaccine Type Change Disease Burden and Cost-Effectiveness in the United States? An Agent-Based Modeling Study. American Journal of Epidemiology, 2017, 185, 822-831.	1.6	13
136	Are children's vitamin D levels and BMI associated with antibody titers produced in response to 2014–2015 influenza vaccine?. Human Vaccines and Immunotherapeutics, 2017, 13, 1661-1665.	1.4	13
137	Influenza vaccination coverage among persons seeking outpatient medical care for acute respiratory illness in five states in the United States, 2011–2012 through 2018–2019. Vaccine, 2021, 39, 1788-1796.	1.7	13
138	Vaccine Effectiveness Against Influenza-Associated Hospitalizations Among Adults, 2018–2019, US Hospitalized Adult Influenza Vaccine Effectiveness Network. Journal of Infectious Diseases, 2021, 224, 151-163.	1.9	13
139	Effects of the year 2000 influenza vaccine delay on elderly patients' attitudes and behaviors. Preventive Medicine, 2003, 37, 417-423.	1.6	12
140	Feasibility of influenza immunization for inner-city children aged 6 to 23 months. American Journal of Preventive Medicine, 2004, 27, 397-403.	1.6	12
141	Using the 4 Pillarsâ,,¢ Practice Transformation Program to increase adult Tdap immunization in a randomized controlled cluster trial. Vaccine, 2016, 34, 5026-5033.	1.7	12
142	Cost-effectiveness of adult pneumococcal vaccination policies in underserved minorities aged 50–64†years compared to the US general population. Vaccine, 2019, 37, 2026-2033.	1.7	12
143	Tailoring Interventions: Understanding Medical Practice Culture. Journal of Cross-Cultural Gerontology, 2004, 19, 47-76.	0.5	11
144	Cost Effectiveness of Influenza Vaccine for U.S. Children. American Journal of Preventive Medicine, 2016, 51, 309-317.	1.6	11

#	Article	IF	CITATIONS
145	Costâ€Effectiveness of the 4 Pillars Practice Transformation Program to Improve Vaccination of Adults Aged 65 and Older. Journal of the American Geriatrics Society, 2017, 65, 763-768.	1.3	11
146	Using the 4 Pillarsâ,,¢ Practice Transformation Program to increase adolescent human papillomavirus, meningococcal, tetanus-diphtheria-pertussis and influenza vaccination. Vaccine, 2017, 35, 6180-6186.	1.7	11
147	Cost-effectiveness and public health impact of alternative influenza vaccination strategies in high-risk adults. Vaccine, 2017, 35, 5708-5713.	1.7	11
148	Racial Disparities in Adult Pneumococcal Vaccination Indications and Pneumococcal Hospitalizations in the U.S Journal of the National Medical Association, 2019, 111, 540-545.	0.6	11
149	Age, revaccination, and tolerance effects on pneumococcal vaccination strategies in the elderly: A cost-effectiveness analysis. Vaccine, 2009, 27, 3159-3164.	1.7	10
150	Association of State Laws and Healthcare Workers' Influenza Vaccination Rates. Journal of the National Medical Association, 2016, 108, 99-102.	0.6	10
151	A randomized controlled trial of antibody response to 2018–19 cell-based vs. egg-based quadrivalent inactivated influenza vaccine in children. Vaccine, 2020, 38, 5171-5177.	1.7	10
152	Higher-Valency Pneumococcal Conjugate Vaccines: An Exploratory Cost-Effectiveness Analysis in U.S. Seniors. American Journal of Preventive Medicine, 2021, 61, 28-36.	1.6	10
153	Estimated Costs Associated with Improving Influenza Vaccination for Health Care Personnel in a Multihospital Health System. Joint Commission Journal on Quality and Patient Safety, 2012, 38, 67-72.	0.4	9
154	Ethical analyses of institutional measures to increase health care worker influenza vaccination rates. Vaccine, 2013, 31, 6172-6176.	1.7	9
155	Hospital Policies, State Laws, and Healthcare Worker Influenza Vaccination Rates. Infection Control and Hospital Epidemiology, 2013, 34, 854-857.	1.0	9
156	Cost-effectiveness of programs to eliminate disparities in elderly vaccination rates in the United States. BMC Public Health, 2014, 14, 718.	1.2	9
157	An intervention to improve pneumococcal vaccination uptake in high risk 50-64 year olds vs. expanded age-based recommendations: an exploratory cost-effectiveness analysis. Human Vaccines and Immunotherapeutics, 2019, 15, 863-872.	1.4	9
158	Influenza Vaccine Effectiveness and Statin Use Among Adults in the United States, 2011–2017. Clinical Infectious Diseases, 2019, 68, 1616-1622.	2.9	9
159	Pneumococcal Vaccination in Adults Aged ≥65 Years: Cost-Effectiveness and Health Impact in U.S. Populations. American Journal of Preventive Medicine, 2020, 58, 487-495.	1.6	9
160	Cost-effectiveness of pneumococcal polysaccharide vaccine among healthcare workers during an influenza pandemic. American Journal of Managed Care, 2010, 16, 200-6.	0.8	9
161	Impact of Low Rates of Influenza on Next-Season Influenza Infections. American Journal of Preventive Medicine, 2022, 62, 503-510.	1.6	9
162	Interventions over 2 years to increase influenza vaccination of children aged 6–23 months in inner-city family health centers. Vaccine, 2006, 24, 1523-1529.	1.7	8

#	Article	IF	CITATIONS
163	Cell-Mediated Immunity Against Antigenically Drifted Influenza A(H3N2) Viruses in Children During a Vaccine Mismatch Season. Journal of Infectious Diseases, 2016, 214, 1030-1038.	1.9	8
164	Maintenance of Increased Childhood Influenza Vaccination Rates 1 Year After an Intervention in Primary Care Practices. Academic Pediatrics, 2016, 16, 57-63.	1.0	8
165	Cost Effectiveness of Influenza Vaccine Choices in Children Aged 2–8 Years in the U.S American Journal of Preventive Medicine, 2016, 50, 600-608.	1.6	8
166	Differential gene expression elicited by children in response to the 2015–16 live attenuated versus inactivated influenza vaccine. Vaccine, 2017, 35, 6893-6897.	1.7	8
167	Inflammatory Mediator Expression Associated With Antibody Response Induced by Live Attenuated vs Inactivated Influenza Virus Vaccine in Children. Open Forum Infectious Diseases, 2018, 5, ofy277.	0.4	8
168	Does influenza vaccination status change physician ordering patterns for respiratory viral panels? Inspection for selection bias. Human Vaccines and Immunotherapeutics, 2019, 15, 91-96.	1.4	8
169	SARS-CoV-2 Antibody Response Is Associated with Age and Body Mass Index in Convalescent Outpatients. Journal of Immunology, 2022, 208, 1711-1718.	0.4	8
170	Cost-Effectiveness of a Program to Eliminate Disparities in Pneumococcal Vaccination Rates in Elderly Minority Populations: An Exploratory Analysis. Value in Health, 2013, 16, 311-317.	0.1	7
171	Reducing Racial Disparities in Influenza Vaccination Among Children With Asthma. Journal of Pediatric Health Care, 2016, 30, 208-215.	0.6	7
172	Impact of seasonal influenza vaccination in the presence of vaccine interference. Vaccine, 2018, 36, 853-858.	1.7	7
173	Cost-Effectiveness of Pneumococcal VaccinationÂand Uptake ImprovementÂPrograms in Underserved and General Population Adults Aged < 65ÂYears. Journal of Community Health, 2020, 45, 111-120.	1.9	7
174	Costâ€Effectiveness of Pneumococcal Vaccination Policies and Uptake Programs in US Older Populations. Journal of the American Geriatrics Society, 2020, 68, 1271-1278.	1.3	7
175	Reducing Antibiotic Use in Ambulatory Care Through Influenza Vaccination. Clinical Infectious Diseases, 2020, 71, e726-e734.	2.9	7
176	Agreement among sources of adult influenza vaccination in the age of immunization information systems. Vaccine, 2021, 39, 6829-6836.	1.7	7
177	Estimating the burden of adult hospitalized RSV infection using local and state data - methodology. Human Vaccines and Immunotherapeutics, 2022, 18, 1958610.	1.4	7
178	Impact of vaccine economic programs on physician referral of children to public vaccine clinics: a pre-post comparison. BMC Public Health, 2006, 6, 7.	1.2	6
179	Using a Mixed Methods Approach to Examine Practice Characteristics Associated With Implementation of an Adult Immunization Intervention Using the 4 Pillars Practice Transformation Program. Journal for Healthcare Quality: Official Publication of the National Association for Healthcare Quality, 2017,	0.3	6
180	Cost-effectiveness of pneumococcal and influenza vaccination standing order programs. American Journal of Managed Care, 2013, 19, e30-7.	0.8	6

#	Article	IF	CITATIONS
181	A randomized controlled trial of antibody response to 2019–20 cell-based inactivated and egg-based live attenuated influenza vaccines in children and young adults. Vaccine, 2022, 40, 780-788.	1.7	6
182	Impact of diabetes status on immunogenicity of trivalent inactivated influenza vaccine in older adults. Influenza and Other Respiratory Viruses, 2022, 16, 562-567.	1.5	6
183	Impact of the 2004 Influenza Vaccine Shortage on Patients from Inner City Health Centers. Journal of Urban Health, 2007, 84, 389-399.	1.8	5
184	Increasing engagement of clinicians in adult immunizations: Reflections on a decade and a half of research. Vaccine, 2014, 32, 7040-7042.	1.7	5
185	Detection of Influenza Virus Infection Using Two PCR Methods. Advances in Virology, 2014, 2014, 1-3.	0.5	5
186	Influenza vaccine effectiveness among outpatients in the US Influenza Vaccine Effectiveness Network by study site 2011â€⊋016. Influenza and Other Respiratory Viruses, 2020, 14, 380-390.	1.5	5
187	Cost effectiveness of a practice-based intervention to improve vaccination rates in adults less than 65-years-old. Human Vaccines and Immunotherapeutics, 2017, 13, 2207-2212.	1.4	4
188	Compressed Influenza Vaccination in U.S. Older Adults: A Decision Analysis. American Journal of Preventive Medicine, 2019, 56, e135-e141.	1.6	4
189	Hospitalization following outpatient medical care for influenza: <scp>US</scp> influenza vaccine effectiveness network, 2011â€12—2015â€16. Influenza and Other Respiratory Viruses, 2019, 13, 133-137.	1.5	4
190	OUP accepted manuscript. American Journal of Epidemiology, 2021, , .	1.6	4
191	Recommended childhood and adolescent immunization schedule, United States, 2003 and update on childhood immunizations. American Family Physician, 2003, 67, 188, 190, 195-6.	0.1	4
192	Multiplex Detection of Antibody Landscapes to SARS-CoV-2/Influenza/Common Human Coronaviruses Following Vaccination or Infection with SARS-CoV-2 and Influenza. Clinical Infectious Diseases, 0, , .	2.9	4
193	If pneumonia is the "old man's friendâ€; should it be prevented by vaccination? An ethical analysis. Vaccine, 2005, 23, 3843-3849.	1.7	3
194	Assessing Disparities in Adult Vaccination Using Multimodal Approaches in Primary Care Offices: Methodology. Journal of Urban Health, 2008, 85, 217-227.	1.8	3
195	Using Quantitative and Qualitative Approaches to Understand Racial Disparities in Adult Vaccination. Journal of the National Medical Association, 2009, 101, 1052-1060.	0.6	3
196	The Comparative Value of Various Employer-Sponsored Influenza Vaccination Clinics. Journal of Occupational and Environmental Medicine, 2012, 54, 1107-1117.	0.9	3
197	The effect of perceived psychological stress on the immunogenicity of the quadrivalent human papillomavirus vaccine in males. Human Vaccines and Immunotherapeutics, 2017, 13, 676-679.	1.4	3
198	Potential Cost-Effectiveness of a Universal Influenza Vaccine in Older Adults. Innovation in Aging, 2018, 2, igy035.	0.0	3

#	Article	IF	CITATIONS
199	Exploring the potential public health benefits of universal influenza vaccine. Human Vaccines and Immunotherapeutics, 2019, 15, 2919-2926.	1.4	3
200	Rationing of Civilian Coronavirus Disease 2019 Vaccines While Supplies Are Limited. Journal of Infectious Diseases, 2020, 222, 1776-1779.	1.9	3
201	Comparison of local influenza vaccine effectiveness using two methods. Vaccine, 2021, 39, 1283-1289.	1.7	3
202	Keeping Up-to-Date with Immunization Practices. Primary Care - Clinics in Office Practice, 2011, 38, 747-761.	0.7	2
203	Intention to Receive Influenza Vaccine after an Acute Respiratory Illness. American Journal of Health Behavior, 2015, 39, 573-581.	0.6	2
204	Influenza Vaccine Intention After a Medically Attended Acute Respiratory Infection. Health Promotion Practice, 2019, 20, 539-552.	0.9	2
205	Differences between Frequentist and Bayesian inference in routine surveillance for influenza vaccine effectiveness: a test-negative case-control study. BMC Public Health, 2021, 21, 516.	1.2	2
206	Sample size considerations for mid-season estimates from a large influenza vaccine effectiveness network in the United States. Vaccine, 2021, 39, 3324-3328.	1.7	2
207	Clinical Influenza Testing Practices in Hospitalized Children at United States Medical Centers, 2015-2018. Journal of the Pediatric Infectious Diseases Society, 2022, 11, 5-8.	0.6	2
208	Using captureâ€recapture methods to estimate influenza hospitalization incidence rates. Influenza and Other Respiratory Viruses, 2022, 16, 308-315.	1.5	2
209	The 2002 United States varicella vaccine shortage and physician recommendations for vaccination. Preventive Medicine, 2005, 41, 575-582.	1.6	1
210	650Relative Vaccine Effectiveness of Live-Attenuated Versus Inactivated Influenza Vaccines in Children and Adolescents Aged 2–18 Years in Two Seasons – US Flu VE Network. Open Forum Infectious Diseases, 2014, 1, S35-S35.	0.4	1
211	Potential Consequences of Not Using Live Attenuated Influenza Vaccine. American Journal of Preventive Medicine, 2017, 53, 500-503.	1.6	1
212	Prior-Season Vaccination and Risk of Influenza During the 2014–2015 Season in the United States. Journal of Infectious Diseases, 2017, 216, 284-285.	1.9	1
213	Reply to: Estimating the Full Value of Highâ€Đose Influenza Vaccine. Journal of the American Geriatrics Society, 2017, 65, 2111-2112.	1.3	1
214	Should older adult pneumococcal vaccination recommendations change due to decreased vaccination in children during the pandemic? A cost-effectiveness analysis. Vaccine, 2021, 39, 4278-4282.	1.7	1
215	Is further research on adult pneumococcal vaccine uptake improvement programs worthwhile? I [°] value of information analysis. Vaccine, 2021, 39, 3608-3613.	1.7	1
216	Vaccine-associated attenuation of subjective severity among outpatients with influenza. Vaccine, 2022, 40, 4322-4327.	1.7	1

#	Article	IF	CITATIONS
217	An overview of the National Network for Immunization Information's Website. Vaccine, 2009, 27, 965.	1.7	0
218	Steps for clinicians and public health officials to take to reach persons of faith, for the sake of protecting all against vaccine-preventable diseases. Vaccine, 2013, 31, 2009-2010.	1.7	0
219	535Effectiveness of Seasonal Influenza Vaccines against Influenza A(H1N1)pdm09 Illness during Three Influenza Seasons, US Flu VE Network. Open Forum Infectious Diseases, 2014, 1, S20-S20.	0.4	0
220	1055Antibody Response to Intradermal and High Dose Influenza Vaccine in 2012-13 Among Adults Who Did and Did Not Respond to Standard Dose Vaccine in 2011-12. Open Forum Infectious Diseases, 2014, 1, S309-S309.	0.4	0
221	1125Viral Infections In Outpatients With Medically Attended Acute Respiratory Illness During the 2012-13 Influenza Season. Open Forum Infectious Diseases, 2014, 1, S334-S334.	0.4	0
222	Are plasma mineral levels related to antibody response to influenza vaccination in older adults?. Human Vaccines and Immunotherapeutics, 2016, 12, 1003-1008.	1.4	0
223	Differential Gene Expression Elicited by Children in Response to the 2015–2016 Live Attenuated vs. Inactivated Influenza Vaccine. Open Forum Infectious Diseases, 2017, 4, S324-S324.	0.4	0
224	When to Order a Respiratory Viral Panel (RVP): Physician Use in Clinical Practice. Open Forum Infectious Diseases, 2017, 4, S354-S354.	0.4	0
225	995. Effectiveness of Influenza Vaccine for Prevention of Influenza-Associated Hospitalizations Among High-Risk Adults in the United States, 2015–2016. Open Forum Infectious Diseases, 2018, 5, S296-S296.	0.4	0
226	150. Relative Effectiveness of High-Dose and Standard-Dose Influenza Vaccine Against Influenza-Related Hospitalization Among Older Adults—United States, 2015–2017. Open Forum Infectious Diseases, 2018, 5, S10-S10.	0.4	0
227	Determination of Eligibility for Influenza Research: A Clinical Informatics Approach. Open Forum Infectious Diseases, 2019, 6, ofz231.	0.4	0
228	Models of Health Behavior and Systems and Overcoming Barriers to Improved Immunization Rates. , 2017, , 235-271.		0
229	A Novel Representation of Vaccine Efficacy Trial Datasets for Use in Computer Simulation of Vaccination Policy. AMIA Summits on Translational Science Proceedings, 2018, 2017, 389-398.	0.4	0
230	The 2004 Recommended Adult Immunization Schedule. American Family Physician, 2003, 68, 2453-6.	0.1	0